A cute kidney injury (AKI) affects up to half of patients admitted to the ICU (1-4). The incidence of AKI is increasing rapidly, leaving a growing population of survivors for whom optimal care has not been defined (1) (2) (3) (4) . Most post-AKI research focuses on its long-term impact on organ function. However, less attention is paid to outcomes such as quality of life and functional status (5) .
Frailty is a multidimensional condition denoted by a "loss of physiologic reserve and the ability to resist stressors" (6, 7) . Although associated with aging, frailty is observed in younger patients with acute and chronic diseases and predicts subsequent hospitalizations, functional decline, and death (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . This is particularly salient to AKI survivors who experience these outcomes at markedly elevated rates; however, the mechanisms driving this relationship remain unclear.
Although AKI often occurs in patients with multiple comorbidities that may contribute to frailty, AKI may directly promote frailty even after recovery from the acute illness. We hypothesized that among critically ill patients who survived to hospital discharge, AKI would be associated with higher frailty scores at 3 and 12 months. To test this hypothesis, we used data from the prospective Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors (BRAIN-ICU) cohort of critically ill patients who were assessed at baseline, 3 months, and 12 months using the Clinical Frailty Scale (CFS) (9, 18, 19) .
MATERIALS AND METHODS

Study Setting and Design
The BRAIN-ICU study is a prospective cohort of critically ill adults (age, ≥ 18 yr old) with acute respiratory failure and/or shock (septic or cardiogenic) enrolled between 2007 and 2010 at five medical centers (9, 18, 20) . Follow-up occurred at 3 and 12 months postdischarge. We have previously described BRAIN-ICU enrollment in detail (9, 18, 20) . Briefly, patients with recent ICU exposure (i.e., mechanical ventilation within 2 mo, 5 ICU days within the prior month), an expected survival of less than 24 hours, inability to be reliably assessed for delirium (i.e., blindness, deafness, or non-English speaking), and a high likelihood of preexisting cognitive deficits (e.g., neurodegenerative disease, anoxic brain injury, severe dementia) were excluded from the parent study. For this secondary analysis, we restricted the cohort to participants who were enrolled at Vanderbilt University Medical Center because daily serum creatinines were available for this group. Additional exclusion criteria unique to these analyses were (Fig. 1) end-stage renal , history of kidney transplant, or receiving maintenance dialysis; n = 36), missing Sequential Organ Failure Assessment (SOFA) scores (n = 2), death prior to hospital discharge (n = 83), or alive but absent from both the 3-and 12-month follow-up visits (n = 27). Written informed consent was obtained from all participants and/or their surrogates. The study was approved by the Vanderbilt University Medical Center Institutional Review Board.
Baseline Kidney Function and AKI
We estimated baseline kidney function by using the mean of all outpatient serum creatinine values from 7 to 365 days prior to the index admission (21) . If the mean outpatient serum creatinine was not available, we used the lowest serum creatinine during the hospitalization as the baseline creatinine (22) . To improve accuracy, we performed clinical adjudication of baseline serum creatinine in two settings: first, if the lowest serum creatinine during the hospitalization was greater than or equal to 0.5 mg/ dL below the mean of all outpatient serum creatinines from 7 to 365 days prior to index admission; and second, for patients with a baseline serum creatinine that resulted in an eGFR less than 60 mL/min/1.73 m 2 . In these settings, two nephrologists (K.A.-K., E.D.S.) blinded to outcomes reviewed the electronic health record (EHR), including scanned documents, to adjudicate baseline serum creatinine by consensus. Differences in baseline creatinine values between the nephrologists were nearly always on the order of 0.1 mg/dL. Notably, 21 patients' baseline creatinine values were adjusted by clinical adjudication. We used baseline creatinine values to calculate the baseline eGFR from the Chronic Kidney Disease-Epidemiology Collaboration equation (23) .
We determined AKI status (i.e., exposure of interest) using serum creatinine values collected during routine clinical care. In the vast majority of cases, patients' serum creatinine values were available daily. We staged AKI according to Kidney Disease Improving Global Outcomes (KDIGO) creatinine criteria using the difference between baseline and peak serum creatinine (i.e., peak injury) (24) . Specifically, stage 1 injury required a 50% increase from baseline creatinine or an absolute increase in baseline creatinine of greater than or equal to 0.3 mg/dL, stage 2 injury required a greater than or equal to 100% increase from baseline serum creatinine, and stage 3 injury required a greater than or equal to 200% increase from baseline serum creatinine or initiation of dialysis.
In addition, to examine the relationship between unresolved AKI at hospital discharge and frailty, we a priori decided to calculate KDIGO stages at hospital discharge using the serum creatinine in closest proximity to discharge (i.e., injury at discharge). To examine the potential effect of dialysis on the association between AKI and frailty, we also included receipt of dialysis at the time of discharge as a separate covariate in a supplemental analysis. Further, to examine the impact of timing of AKI onset, we adjusted for peak injury occurring within 48 hours (i.e., peak creatinine within 48 hr of admission) versus beyond 48 hours in a supplemental analysis.
Covariates
In addition to baseline kidney function, we also chose to adjust for the following potential confounders, selected a priori based on biologic plausibility and prior research (9, 17, 22, 25, 26) : age, gender, race, modified Charlson Comorbidity Index (CCI) (27) , mean modified SOFA score (28) , Acute Physiology and Chronic Health Evaluation II (APACHE II) score (29) , and baseline CFS score (described below). We modified the CCI and SOFA to remove the renal components of these indices because they were included separately in our analyses. In a supplemental analysis, we also controlled for length of study time mechanically ventilated to further adjust for potential differences in severity of illness. In the 11% of patients who were not mechanically ventilated (evenly distributed between exposure arms), the time mechanically ventilated was set to 0. We did not include length of hospital stay as a covariate because AKI has been consistently associated with longer hospital admissions, often related to monitoring of kidney function (22) . All covariates were assessed at enrollment or during the enrollment hospitalization (e.g., SOFA scores) only and were not updated following discharge.
Clinical Frailty Assessment
Upon enrollment (i.e., within 72 hr of ICU admission), study team members, trained by a geriatrician with frailty expertise, interviewed the patient and/or surrogate and reviewed the EHR to determine a prehospitalization CFS score (i.e., baseline CFS score). The CFS is a validated measure of clinical frailty with scores that range from 1 (very fit) to 7 (severely frail/terminally ill) (19, 30) . Scores greater than or equal to 5 indicate the presence of clinical frailty. Because every point increase in CFS score has been associated with poorer outcomes (19, 30) , we analyzed the CFS as an ordinal measure (31) (32) (33) (34) .
At 3-and 12-month follow-up, trained study team members, who were blinded to the events of the ICU course, conducted in-person CFS assessments. Because CFS scores at ICU admission were associated with mortality (9), we a priori chose to categorize death as a CFS score of 8 to reduce the effect of survivor bias in our primary analyses. In sensitivity analyses (described below), we used the 1-7 CFS scoring system and excluded patients who died before the respective follow-up time point.
Statistical Analysis
Because CFS is an ordinal response variable (31-34), we used ordinal logistic regression to model the dependency of CFS on AKI status while adjusting for potential clinical and demographic confounders. We fit separate models for different markers of AKI, for example, peak AKI stage and discharge AKI stage. Sociodemographic covariates of interest were age, gender, and race. Clinical covariates were baseline (i.e., preillness) CFS score, modified CCI score, modified mean daily SOFA score, APACHE II score, baseline creatinine, and days mechanically ventilated. We included age as a nonlinear term in the models using restricted cubic splines with three knots. We modeled baseline creatinine both as a linear term as well as
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In sensitivity analyses, we repeated our main analyses while: 1) restricting the cohort to patients with a known outpatient baseline creatinine (n = 177); 2) restricting the cohort to patients with a baseline CFS score less than or equal to 5 (i.e., mildly frail or better); and 3) restricting the cohort to survivors at 3 or 12 months, respectively (in order to understand better whether the association between AKI and frailty was driven primarily by death). Because of the smaller sample size in the analysis restricted to survivors, we combined AKI stages 2 and 3. All analyses use 95% CIs. Analyses were performed using R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria) (35) .
RESULTS
For our primary analyses, 371 patients met inclusion criteria (parent cohort, Fig. 1 ). Of these, 317 and 318 were in our analytic cohorts at 3 and 12 months, respectively (Fig. 1) . In the analytic cohort, at baseline, participants had a median age of 57 years, 90% were white, median nonrenal SOFA score at enrollment was 8, and median APACHE II score was 25. Participants had a median nonrenal Charlson score of 2 and median baseline creatinine of 0.9 ( Table 1) . At baseline, 75 of 317 participants (24%) were clinically frail (Table 1 ). AKI occurred in 243 patients (77%) and was still present at discharge in 87 patients (27%) ( Table 1) . Approximately, 27% (65/243) versus 13% (10/74) of AKI and non-AKI patients were considered frail at baseline (i.e., CFS ≥ 5), respectively (Table 1 and Fig. 2A) . At 3-and 12-month follow-up, unadjusted CFS scores increased in all groups compared with baseline, and about 50-62% of AKI patients were considered clinically frail (Fig. 2, B 
Association Between Peak AKI and Frailty
In fully adjusted models, relative to no AKI, peak AKI stages 1, 2, and 3 were associated with higher CFS scores at 3 months (OR, 1.92; 95% CI, 1.14-3.24; OR, 2.40; 95% CI, 1.31-4.42; and OR, 4.41; 95% CI, 2.20-8.82, respectively; Table 2 ). Similarly, peak AKI was generally associated with higher CFS scores at 12 months (AKI stage 1: OR, 1.87; 95% CI, 1.11-3.14; AKI stage 2: OR, 1.81; 95% CI, 0.94-3.48; and AKI stage 3: OR, 2.76; 95% CI, 1.34-5.66; Table 2 ). The fully adjusted probabilities of having a CFS score that increased from 4 (apparently vulnerable) or less to 5 or greater (frail) based on peak AKI stage are shown in Figure 3 . There was no significant interaction between AKI stage and baseline creatinine in any of the peak AKI and frailty analyses.
Supplemental Analyses
In fully adjusted models, AKI stages 2 and 3 at discharge were associated with higher CFS scores at 3 months (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D243). At 12 months, AKI stage 3 at discharge remained associated with higher CFS scores, whereas AKI stages 1 and 2 at discharge trended toward an association (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D243).
When adjusting for dialysis status at discharge, the findings were similar; AKI was associated with higher CFS scores at 3 and 12 months (Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/D243). In addition, when adjusting for timing of AKI onset as a covariate (peak creatinine, ≤ 48 vs > 48 hr), the findings were similar; AKI was associated with higher CFS scores at 3 and 12 months (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/D243). Notably, the timing of AKI (> 48 hr) was also associated with frailty status; however, controlling for this did not abrogate the association between AKI and frailty, which remained robust (Supplemental Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/ D243). When adjusting for length of study time mechanically ventilated, the results were similar with AKI stages 1 and 3 associated with higher CFS scores at 3 and 12 months (Supplemental Table 4 , Supplemental Digital Content 1, http://links.lww.com/CCM/D243).
Sensitivity Analyses
In the sensitivity analysis restricted to patients with a known outpatient baseline creatinine (Supplemental Table 5 In analyses restricted to patients with baseline CFS score less than or equal to 5 (i.e., mildly frail), the main results were unchanged; AKI stages were associated with higher CFS scores at 3 and 12 months (Supplemental Table 6 , Supplemental Digital Content 1, http://links.lww.com/CCM/D243). In the sensitivity analysis restricted to survivors at 3 or 12 months, AKI stage 1 was not associated with CFS score at 3 months but bordered on an association with higher CFS scores at 12 months (3 mo: OR, 1.59; 95% CI, 0.88-2.88; 12 mo: OR, 1.85; 95% CI, 0.97-3.53, respectively). Conversely, AKI stage 2+ was associated with higher CFS scores at 3 months only (3 mo: OR, 2.11; 95% CI, 1.14-3.91; 12 mo: OR, 1.13; 95% CI, 0.58-2.19; Supplemental Table 7 , Supplemental Digital Content 1, http:// links.lww.com/CCM/D243).
DISCUSSION
In this study, we demonstrated that more than half of the survivors of critical illness who experienced AKI were frail at 3 and 12 months after hospital discharge. Further, AKI was associated with worse clinical frailty scores in survivors after adjusting for illness severity. This relationship was robust for (4) 13 (5) 2: well 15 (20) 37 (15) 3: well, with comorbidities 33 (45) 82 (34) 4: apparently vulnerable 13 (18) 46 (19) 5: mildly frail 7 (9) 29 (12) 6: moderately frail 3 (4) 29 (12) 7: severely frail 0 (0) 7 (3) severe AKI (KDIGO stage 3) and appeared stronger if injury persisted to hospital discharge. Our data suggest that AKI may play a role in the link between kidney disease and frailty. Although our analyses cannot establish causality, potential renal-specific contributions to frailty include the well-recognized complications of volume overload (36), which may limit mobility and physical exertion; anemia (37) , which can contribute to fatigue and decreased physical activity; and potential cognitive deficits (20, 38) and medication toxicities (39) . Furthermore, AKI has been consistently associated with longer hospital stays (22) , which may worsen muscle deconditioning (40) . AKI is also associated with subclinical pathophysiologic changes including inflammation, immune compromise, and metabolic derangements (36, 41, 42) . These effects may be especially evident in patients with more severe AKI or in those who do not recover from their AKI. Future studies are needed to clarify whether the intersection of AKI and frailty results from the kidneys acting as a sensitive and easily assessed barometer of clinical status and/or the deleterious effects of AKI on health.
The American Society of Nephrology has identified the transition of care following AKI as an opportunity to improve longterm outcomes of the disease (43) . This has become especially important in light of reports highlighting a rapid growth in the incidence of AKI (44) . To our knowledge, this is the first study to examine the effect of AKI on frailty. For critical care providers, our findings highlight that critical illness survivors with AKI, especially those with severe or persistent injury, are at higher risk for clinical frailty for a prolonged duration. Interventions such as physical rehabilitation (including home-based therapy), nutritional evaluation and supplementation (and homebased meal assistance if necessary), and psychosocial support (including psychiatric evaluation and efforts to increase social engagement) may improve or mitigate the development of frailty (45) . Hence, close attention to these factors is necessary, especially during transitions of care. Further, our findings may inform patient and family discussions regarding the increased likelihood for a prolonged rehabilitation and for experiencing important patient-centered manifestations of clinical frailty, such as fatigue, slowing, and decrements in independence.
In patients with CKD, frailty correlates with quality of life and is an important prognostic marker (8, 10, 11, (46) (47) (48) . In addition, frail incident ESRD patients are more than three times as likely to die within 1 year of initiating dialysis. Hence, frailty is an important consideration that informs dialysis decision making in this population (8, (47) (48) (49) . Because patients who survive severe AKI are at the highest risk for developing advanced stages of CKD and ESRD, the high prevalence of frailty in this population suggests that routine assessments be considered (50) . Future studies will need to determine the impact of frailty on recovery from AKI and downstream outcomes and whether interventions that can decrease frailty can improve clinical and patient-centered outcomes. Because survivors of severe AKI often suffer marked declines in quality of life (25) , additional information to guide patient and clinician decision making is essential (50) .
Although we observed an association between frailty and AKI in survivors of critical illness, this relationship was attenuated in our 12-month analysis that excluded death. Patients with the most severe AKI die at markedly elevated rates, which may limit longitudinal assessments in some patients leaving relatively healthier survivors (Supplemental Table 8 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D243). We attempted to address these issues by including death as the most severe frailty score, under the assumption that decedents had worsened frailty status shortly prior to death. However, some decedents may have died from sudden events that were not preceded by frailty. Reassuringly, 85% of patients with AKI 2+ who died between 3 and 12 months were clinically frail at their 3-month assessment (data not shown). Furthermore, our sensitivity analyses continued to support an association between AKI 2+ and frailty at 3-month follow-up after excluding patients who died.
Our study has several notable strengths: we systematically measured CFS at baseline and longitudinally in a critically ill cohort, follow-up rates were high given the cohort disease burden, and creatinine data were available to provide granular phenotyping of AKI. Our study also has several important limitations. First, this was a single-center study that requires confirmation, and our findings may not be generalizable to the extremely healthy or the severely chronically ill, as few patients had baseline CFS scores in this range. Second, the observational design of this study is unable to determine whether the association between AKI and frailty was causative; we did not have data to explore postulated mediators of the AKI-frailty association further and residual confounding may be present. Third, although the CFS is pragmatic, validated, and well-suited for use in critically ill patients, it is subjective and may not optimally differentiate patients across the spectrum of frailty. However, referent frailty instruments often include performance-based measures that are quite difficult to obtain in patients with acute critical illness and provider-based clinical frailty assessments appear to perform comparably to more objective measures (51, 52) . Fourth, we did not have an outpatient assessment of baseline kidney function in all patients. However, our sensitivity analyses continued to demonstrate an association between severe AKI and frailty score. Fifth, the relatively few patients in the non-AKI exposure arm, which is expected in an ICU study requiring acute respiratory failure or shock, is a potential challenge for generalizing the results of non-AKI subjects. Sixth, we did not adjudicate patients' AKI etiology. However, because the cohort consisted of ICU patients with a high severity of illness and shock, we anticipate 
CONCLUSIONS
In conclusion, the majority of survivors of critical illness complicated by AKI are clinically frail at 3 and 12 months after discharge, and AKI is independently associated with frailty. Further research is needed to understand potential mechanistic links and the effect of frailty on outcomes in patients in whom AKI was developed during critical illness. Because frailty is associated with functional decline in the critically ill, interventions to maintain independent function among patients who survive AKI are needed. As the U.S. population ages and the incidence of AKI and AKI risk factors increase, such information will be integral to engaging patients and families in informed discussions of treatment options and anticipated outcomes.
